-
公开(公告)号：US5028692A
公开(公告)日：1991-07-02
申请号：US343092
申请日：1989-04-25
申请人： Allen I. Oliff , Walfred S. Saari
发明人： Allen I. Oliff , Walfred S. Saari
IPC分类号： C07K7/02 , C07K7/08 , C07K14/575
CPC分类号： C07K7/02 , C07K14/57572 , C07K7/086
摘要： Small cell lung carcinoma cells (SCLC) contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of peptide derivatives that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting activity of GRP.
摘要翻译： 小细胞肺癌细胞（SCLC）含有胃泌素释放肽（GRP）受体。 细胞对GRP的反应是快速增长。 我们已经发现一组作为GRP拮抗剂的肽衍生物通过阻断GRP与其受体的结合，从而抑制对GRP的生长促进活性敏感的细胞的生长。
-
公开(公告)号：US5019647A
公开(公告)日：1991-05-28
申请号：US197872
申请日：1988-05-24
IPC分类号： A61K38/00 , C07K14/575
CPC分类号： C07K14/575 , A61K38/00
摘要： Small cell lung carcinoma cells (SCLC) contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of peptide derivatives that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting activity of GRP.
-
公开(公告)号：US5047502A
公开(公告)日：1991-09-10
申请号：US389093
申请日：1989-08-03
IPC分类号： A61K38/00 , C07K14/575
CPC分类号： C07K14/57572 , A61K38/00
摘要： Small cell lung carcinoma cells (SCLC) contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of heptapeptides that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting acitivity of GRP.
摘要翻译： 小细胞肺癌细胞（SCLC）含有胃泌素释放肽（GRP）受体。 细胞对GRP的反应是快速增长。 我们已经发现一组作为GRP拮抗剂的七肽通过阻断GRP与其受体的结合，从而抑制对促进GRP活性的生长敏感的细胞的生长。
-
公开(公告)号：US06207798B1
公开(公告)日：2001-03-27
申请号：US08798447
申请日：1997-02-10
IPC分类号： C07K1421
CPC分类号： C07K14/495 , A61K47/642 , C07K14/21 , C07K2319/00 , C07K2319/55 , C07K2319/75
摘要： We have modified PE40 toxin by removing at least two of its four cysteine amino acid residues and have formed hybrid molecules containing modified PE40 linked to a cell recognition protein that can be an antibody, a growth factor, a hormone, a lymphokine, or another polypeptide cell recognition protein for which a specific cellular receptor exists whereby the modified PE40 toxin is directed to cell types having receptors for the cell recognition protein linked to the modified PE40.
摘要翻译： 我们已经通过去除其四个半胱氨酸氨基酸残基中的至少两个而修饰了PE40毒素，并且已经形成了与可以是抗体，生长因子，激素，淋巴因子或其他多肽的细胞识别蛋白连接的修饰的PE40的杂交分子 存在特异性细胞受体的细胞识别蛋白质，其中修饰的PE40毒素针对具有与修饰的PE40连接的细胞识别蛋白的受体的细胞类型。
-
公开(公告)号：US06130204A
公开(公告)日：2000-10-10
申请号：US51342
申请日：1998-04-06
IPC分类号： C12Q1/37 , A61K38/00 , A61K45/00 , A61K47/48 , A61K49/00 , A61P13/02 , A61P15/00 , A61P35/00 , C07K5/10 , C07K5/107 , C07K7/06 , C07K7/08 , C07K14/47 , A61K38/07 , A61K38/08 , A61K38/48
CPC分类号： C07K14/47 , A61K47/48338 , C07K5/1016 , A61K38/00 , C07K2319/00 , Y10S930/28 , Y10S930/30
摘要： Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.
摘要翻译： PCT No.PCT / US96 / 15713 Sec。 371日期：1998年4月6日 102（e）1998年4月6日PCT PCT 1996年10月2日PCT公布。 出版物WO97 / 12624 日期：1997年4月10日描述了包含被游离前列腺特异性抗原（PSA）识别和蛋白水解切割的氨基酸序列的寡肽。 还描述了包含用于在体外和体内测定游离PSA蛋白酶活性的这种寡肽的测定法。 还描述了包含这种寡肽和已知细胞毒性剂的缀合物的治疗剂。
-
公开(公告)号：US5690928A
公开(公告)日：1997-11-25
申请号：US224422
申请日：1994-04-11
IPC分类号： A61K38/00 , A61K47/48 , A61P35/00 , C07K1/22 , C07K1/30 , C07K14/00 , C07K14/195 , C07K14/21 , C07K14/41 , C07K14/415 , C07K14/495 , C07K14/52 , C07K19/00 , C12N5/10 , C12N15/09 , C12P21/02 , C12R1/19 , A61K38/45
CPC分类号： C07K14/495 , A61K47/48261 , A61K47/48269 , C07K14/21 , A61K38/00 , C07K2319/00
摘要： Methods and compositions for treating bladder cancer using TGF-alpha or EGF fused to PE.sub.40 or cysteine modified derivatives are taught. Also, a method of producing TGF-alpha-PE.sub.40 derivatives of enhanced potency is described.
摘要翻译： 教导了使用与PE40或半胱氨酸修饰的衍生物融合的TGF-α或EGF治疗膀胱癌的方法和组合物。 另外，描述了提高效能的TGF-α-PE40衍生物的生产方法。
-
公开(公告)号：US6143864A
公开(公告)日：2000-11-07
申请号：US468161
申请日：1995-06-06
IPC分类号： G01N33/566 , A61K31/195 , A61K38/00 , A61K38/08 , A61K47/48 , A61P13/08 , A61P35/00 , A61P43/00 , C07H15/24 , C07K7/06 , C07K7/08 , C07K14/47 , C07K17/08 , C12Q1/37 , G01N33/574 , A61K38/14 , C07K9/00
CPC分类号： C07K14/47 , A61K47/48238 , A61K47/48338 , A61K38/00
摘要： Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.
摘要翻译： 描述了包含被游离前列腺特异性抗原（PSA）识别和蛋白水解切割的氨基酸序列的寡肽。 还描述了包含用于在体外和体内测定游离PSA蛋白酶活性的这种寡肽的测定法。 还描述了包含这种寡肽和已知细胞毒性剂的缀合物的治疗剂。
-
公开(公告)号：US5866679A
公开(公告)日：1999-02-02
申请号：US540412
申请日：1995-10-06
IPC分类号： C12Q1/37 , A61K38/00 , A61K45/00 , A61K47/48 , A61K49/00 , A61P13/02 , A61P15/00 , A61P35/00 , C07K5/10 , C07K5/107 , C07K7/06 , C07K7/08 , C07K14/47 , C07K5/09
CPC分类号： C07K14/47 , A61K47/48338 , C07K5/1016 , A61K38/00 , C07K2319/00 , Y10S930/28 , Y10S930/30
摘要： Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.
摘要翻译： 描述了包含被游离前列腺特异性抗原（PSA）识别和蛋白水解切割的氨基酸序列的寡肽。 还描述了包含用于在体外和体内测定游离PSA蛋白酶活性的这种寡肽的测定法。 还描述了包含这种寡肽和已知细胞毒性剂的缀合物的治疗剂。
-
9.发明授权
公开(公告)号：US4923878A
公开(公告)日：1990-05-08
申请号：US270323
申请日：1988-11-14
申请人： Joel R. Huff , Allen I. Oliff
发明人： Joel R. Huff , Allen I. Oliff
IPC分类号： C07D491/147 , A61K31/435 , A61K31/445 , A61P35/00 , C07D471/14 , C07D495/14
CPC分类号： A61K31/445
摘要： Compounds of formula I and its pharmaceutically acceptable salts are formulated with a pharmaceutical carrier for the treatment or prevention of neoplastic diesase states sensitive to such treatment in animals including humans ##STR1## wherein: A is an alkyl group having 1-6 carbons;X is oxygen, sulfur, or --NH--;R is hydrogen or an alkyl group having 1-6 carbons; andR.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, a halogen a C.sub.1-6 alkyl group, or C.sub.1-3 alkoxy.
-
公开(公告)号：US06989383B1
公开(公告)日：2006-01-24
申请号：US09445054
申请日：1998-06-04
申请人： Neal Rosen , Laura Sepp-Lorenzino , Mark M. Moasser , Allen I. Oliff , Jackson B. Gibbs , Nancy Kohl , Samuel L. Graham , George C. Prendergast
发明人： Neal Rosen , Laura Sepp-Lorenzino , Mark M. Moasser , Allen I. Oliff , Jackson B. Gibbs , Nancy Kohl , Samuel L. Graham , George C. Prendergast
IPC分类号： A61K31/495 , A61K31/50 , A61K31/335 , A61K31/35 , A61K31/34
CPC分类号： A61K31/415 , A61K31/495 , A61K41/00 , A61K45/06
摘要： The present invention relates to methods of treating cancer using a combination of a compound which is an antineoplastic agent and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at lest two therapeutic agents selected from a group consisting of a compound which is an antineoplastic agent and a compound which is an inhibitor or prenyl-protein transferase. The invention also relates to methods of preparing such compositions.
摘要翻译： 本发明涉及使用抗肿瘤剂化合物和作为异戊烯基 - 蛋白转移酶抑制剂的化合物的组合来治疗癌症的方法，该方法包括以任何顺序依次或同时向所述哺乳动物施用量 至少两种选自由抗肿瘤剂的化合物和作为抑制剂或异戊烯基 - 蛋白质转移酶的化合物组成的组的治疗剂。 本发明还涉及制备这种组合物的方法。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.018 秒)
